Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
LIFE HEALTHCARE GROUP HOLDINGS UNSPON ADR EA REPR 4 ORD ZAR0.00
LTGHY
5
Enerpac Tool
EPAC
US OptionsDetailed Quotes
PVLA250516P20000
- 0.00
- 0.000.00%
15min DelayClose May 2 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest20.00Strike Price0.00Turnover0.00%IV18.23%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier11DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma4.89Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Palvella Therapeutics Newsroom
H.C. Wainwright Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $38
Palvella Therapeutics Analyst Ratings
Promising Potential of QTORIN in Addressing Unmet Needs in Vascular Anomalies: A Buy Recommendation for Palvella Therapeutics
Chardan Capital Initiates Palvella Therapeutics(PVLA.US) With Buy Rating, Announces Target Price $50
Palvella Therapeutics Analyst Ratings
Chardan Initiates Palvella Therapeutics at Buy With $50 Price Target
H.C. Wainwright Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $38
TD Cowen Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $44
Scotiabank Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $50
Palvella Therapeutics: Strong Financial Position and Promising Clinical Pipeline Justify Buy Rating
Palvella Therapeutics Price Target Maintained With a $38.00/Share by HC Wainwright & Co.
Palvella Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Palvella Therapeutics, Maintains $38 Price Target
Palvella Therapeutics (PVLA) Receives a Buy From Scotiabank
Cantor Fitzgerald Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Raises Target Price to $70
Stifel Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $45
Stifel Initiates Palvella Therapeutics(PVLA.US) With Buy Rating, Announces Target Price $45
Palvella Therapeutics Analyst Ratings
JonesTrading Initiates Palvella Therapeutics(PVLA.US) With Buy Rating, Announces Target Price $45
Scotiabank Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $50
Market Insights
Discussing
Trade war escalates: What’s next for Chinese stocks?
🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks
Moo Earnings
Feb 17 19:21
Alibaba Q4 FY2024 Earnings Preview: Predict & Win Big! 🚀
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
